CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.33 USD | +1.53% |
|
-1.48% | -54.61% |
Financials (USD)
| Sales 2024 * | 15.52M | Sales 2025 * | 7.2M | Capitalization | 55.25M |
|---|---|---|---|---|---|
| Net income 2024 * | -57M | Net income 2025 * | -69M | EV / Sales 2024 * | 3.56 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.68 x |
| P/E ratio 2024 * |
-1.05
x | P/E ratio 2025 * |
-1.07
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.83% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.53% | ||
| 1 week | -1.48% | ||
| 1 month | -18.40% | ||
| 3 months | -48.45% | ||
| 6 months | -44.58% | ||
| Current year | -54.61% |
1 week
1.25
1.35
1 month
1.241.67
Current year
1.243.06
1 year
1.249.77
3 years
1.249.77
5 years
1.249.77
10 years
1.249.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
| Director/Board Member | 66 | 22-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.33 | +1.53% | 175,475 |
| 24-05-30 | 1.31 | +1.55% | 146,675 |
| 24-05-29 | 1.29 | -3.73% | 188,952 |
| 24-05-28 | 1.34 | -0.74% | 195,299 |
| 24-05-24 | 1.35 | +7.14% | 190,603 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.33
USD
Average target price
7.6
USD
Spread / Average Target
+471.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -54.61% | 55.25M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- CARM Stock
